Staten Island University Hospital Prince’s Bay awardedPrimary Stroke Certification from The Joint Commission

Staten Island University Hospital (SIUH) Prince’s Bay has earned The Joint Commission’s Gold Seal of Approval® and the American Stroke Association’s Heart-Check mark for Primary Stroke Certification.
SIUH Prince’s Bay underwent a rigorous onsite review in August.  During the visit, a team of Joint Commission reviewers evaluated compliance with related certification standards including the use of evidence-based guidelines for stroke care, adoption of standardized performance measures, composition of the program’s interdisciplinary team, program’s mission and scope of services, stroke policies, EMS protocols, and imaging capabilities.
Joint Commission standards are developed in consultation with health care experts and providers, measurement experts and patients. The reviewers also conducted onsite observations and interviews.
“Primary Stroke Certification recognizes health care organizations committed to fostering continuous quality improvement in patient safety and quality of care,” says Mark Pelletier, RN, MS, chief operating officer, Accreditation and Certification Operations, and chief nursing executive, The Joint Commission. “We commend SIUH Princes’ Bay for using certification to reduce variation in its clinical processes and to strengthen its program structure and management framework for stroke patients.”
“We congratulate SIUH Prince’s Bay for this outstanding achievement,” says Nancy Brown, chief executive officer, the American Stroke Association. “This certification reflects its commitment to providing the highest quality of care for stroke patients.”
“SIUH Prince’s Bay has been the main hospital for the South Shore of Staten Island for many years,” said Yasir El-Sherif, director of the Stroke Services at SIUH. “Now with the Joint Commission certification we will be able to provide top quality care in Stroke to the residents of Staten Island. Our multidisciplinary team is composed of a rather large number of Staten Islanders who are dedicated to helping elevate Neuroscience care to their family, friends and fellow Staten Islanders by constantly driving safety, quality, and compassionate care.”
SIUH’s journey towards the Primary Stroke Certification ramped up two years ago with the creation of a core group and framework led by their stroke program. This team, comprised of multidisciplinary clinical providers and administrative leaders, focused on certification standards, clinical practice guidelines, process improvements, performance measures, and outcomes all while establishing a consistent approach to stroke care.
Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."
The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy